Qube Research & Technologies LTD Supernus Pharmaceuticals, Inc. Transaction History
Qube Research & Technologies LTD
- $72.9 Billion
- Q4 2024
A detailed history of Qube Research & Technologies LTD transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 65,110 shares of SUPN stock, worth $2.04 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
65,110
Previous 100,964
35.51%
Holding current value
$2.04 Million
Previous $3.15 Million
25.22%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding SUPN
# of Institutions
303Shares Held
60.7MCall Options Held
22.3KPut Options Held
6K-
Black Rock Inc. New York, NY10.4MShares$326 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.15MShares$193 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.84MShares$152 Million2.47% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$90.3 Million0.03% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$82.5 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.68B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...